Angelica Vittori1, Michael Orth2, Raymund A C Roos3, Tiago F Outeiro4, Flaviano Giorgini5, Edward J Hollox5. 1. Department of Genetics, University of Leicester, Leicester, UK ; Cell and Molecular Neuroscience Unit, Instituto de Medicina Molecular, Lisboa, Portugal. 2. Department of Neurology, University of Ulm, Ulm, Germany. 3. Leiden University Medical Center, Department of Neurology, The Netherlands. 4. Cell and Molecular Neuroscience Unit, Instituto de Medicina Molecular, Lisboa, Portugal ; Faculdade de Medicina da Universidade de Lisboa, Instituto de Fisiologia, Lisboa, Portugal ; University Medical Center Göttingen, Department of NeuroDegeneration and Restorative Research, Göttingen, Germany. 5. Department of Genetics, University of Leicester, Leicester, UK.
Abstract
BACKGROUND: Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by the abnormal expansion of a CAG triplet repeat tract in the huntingtin gene. While the length of this CAG expansion is the major determinant of the age of onset (AO), other genetic factors have also been shown to play a modulatory role. Recent evidence suggests that neuroinflammation is a pivotal factor in the pathogenesis of HD, and that targeting this process may have important therapeutic ramifications. The human β-defensin 2 (hBD2) - encoded by DEFB4 - is an antimicrobial peptide that exhibits inducible expression in astrocytes during inflammation and is an important regulator of innate and adaptive immune response. Therefore, DEFB4 may contribute to the neuroinflammatory processes observed in HD. OBJECTIVE: In this study we tested the hypothesis that copy number variation (CNV) of the β-defensin region, including DEFB4, modifies the AO in HD. METHODS AND RESULTS: We genotyped β-defensin CNV in 490 HD individuals using the paralogue ratio test and found no association between β-defensin CNV and onset of HD. CONCLUSIONS: We conclude that it is unlikely that DEFB4 plays a role in HD pathogenesis.
BACKGROUND: Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by the abnormal expansion of a CAG triplet repeat tract in the huntingtin gene. While the length of this CAG expansion is the major determinant of the age of onset (AO), other genetic factors have also been shown to play a modulatory role. Recent evidence suggests that neuroinflammation is a pivotal factor in the pathogenesis of HD, and that targeting this process may have important therapeutic ramifications. The human β-defensin 2 (hBD2) - encoded by DEFB4 - is an antimicrobial peptide that exhibits inducible expression in astrocytes during inflammation and is an important regulator of innate and adaptive immune response. Therefore, DEFB4 may contribute to the neuroinflammatory processes observed in HD. OBJECTIVE: In this study we tested the hypothesis that copy number variation (CNV) of the β-defensin region, including DEFB4, modifies the AO in HD. METHODS AND RESULTS: We genotyped β-defensin CNV in 490 HD individuals using the paralogue ratio test and found no association between β-defensin CNV and onset of HD. CONCLUSIONS: We conclude that it is unlikely that DEFB4 plays a role in HD pathogenesis.
Entities:
Keywords:
Genetic modifier; copy number variation; inflammation
Authors: Susanna Campesan; Edward W Green; Carlo Breda; Korrapati V Sathyasaikumar; Paul J Muchowski; Robert Schwarcz; Charalambos P Kyriacou; Flaviano Giorgini Journal: Curr Biol Date: 2011-06-07 Impact factor: 10.834
Authors: Arya Biragyn; Pier Adelchi Ruffini; Cynthia A Leifer; Elena Klyushnenkova; Alexander Shakhov; Oleg Chertov; Aiko K Shirakawa; Joshua M Farber; David M Segal; Joost J Oppenheim; Larry W Kwak Journal: Science Date: 2002-11-01 Impact factor: 47.728
Authors: M Groth; C Wiegand; K Szafranski; K Huse; M Kramer; P Rosenstiel; S Schreiber; J Norgauer; M Platzer Journal: Genes Immun Date: 2010-05-06 Impact factor: 2.676
Authors: R G Snell; J C MacMillan; J P Cheadle; I Fenton; L P Lazarou; P Davies; M E MacDonald; J F Gusella; P S Harper; D J Shaw Journal: Nat Genet Date: 1993-08 Impact factor: 38.330
Authors: Selma M Soyal; Thomas K Felder; Simon Auer; Penelope Hahne; Hannes Oberkofler; Anke Witting; Markus Paulmichl; G Bernhard Landwehrmeyer; Patrick Weydt; Wolfgang Patsch Journal: Hum Mol Genet Date: 2012-05-15 Impact factor: 6.150
Authors: Edward J Hollox; Ulrike Huffmeier; Patrick L J M Zeeuwen; Raquel Palla; Jesús Lascorz; Diana Rodijk-Olthuis; Peter C M van de Kerkhof; Heiko Traupe; Gys de Jongh; Martin den Heijer; André Reis; John A L Armour; Joost Schalkwijk Journal: Nat Genet Date: 2007-12-02 Impact factor: 38.330
Authors: Annette Dalrymple; Edward J Wild; Richard Joubert; Kirupa Sathasivam; Maria Björkqvist; Asa Petersén; Graham S Jackson; Jeremy D Isaacs; Mark Kristiansen; Gillian P Bates; Blair R Leavitt; Geoff Keir; Malcolm Ward; Sarah J Tabrizi Journal: J Proteome Res Date: 2007-06-07 Impact factor: 4.466
Authors: Patrick Weydt; Selma M Soyal; Cinzia Gellera; Stefano Didonato; Claus Weidinger; Hannes Oberkofler; G Bernhard Landwehrmeyer; Wolfgang Patsch Journal: Mol Neurodegener Date: 2009-01-08 Impact factor: 14.195